Key Takeaways
Oscar Health (NYSE: OSCR) is at a pivotal juncture, aiming for a significant financial turnaround in 2026 after a challenging 2025. The company reported a substantial net loss of $443.2 million for the full year 2025, a sharp reversal from a $25.4 million profit in 2024. This deterioration was primarily driven by a worsening Medical Loss Ratio (MLR), which climbed to 87.4% for the full year 2025 from 81.7% in 2024, and reached an alarming 95.4% in the fourth quarter of 2025 alone.
Despite these headwinds, management is projecting a return to profitability in the current fiscal year. For 2026, Oscar forecasts total revenue between $18.7 billion and $19.0 billion, a substantial increase from $11.7 billion in 2025. Crucially, the company expects earnings from operations to land between $250 million and $450 million, indicating a targeted shift back into the black. This ambitious guidance hinges on significant improvements in key operational metrics.
The projected MLR for 2026 is set to improve dramatically, targeting a range of 82.4% to 83.4%. This reduction is critical, as the MLR directly reflects the percentage of premium revenue spent on members' medical claims. Concurrently, the Selling, General & Administrative (SG&A) expense ratio is also expected to decline, from 17.5% in 2025 to a range of 15.8% to 16.3% in 2026. These combined improvements are essential for Oscar to achieve its stated profitability goals and demonstrate the effectiveness of its cost management strategies under CEO Mark Bertolini.
Oscar's ability to execute on these targets will be closely watched by investors. The company's stock currently trades at $18.04, reflecting a market capitalization of $4.68 billion. While its P/S ratio stands at a low 0.40, reflecting market skepticism, a successful pivot to consistent profitability could unlock a significant rerating. The path forward requires not just top-line growth, but disciplined cost control and effective risk management in a highly competitive and regulated industry.
Oscar Health's core differentiator lies in its technology-first approach to health insurance, a strategy designed to enhance unit economics and deepen member engagement. The company's proprietary tech stack, including its +Oscar platform, is not merely a convenience; it's an operational engine that aims to lower costs and improve health outcomes. This digital infrastructure underpins everything from claims processing to personalized care navigation, setting Oscar apart from many legacy insurers burdened by outdated systems.
One key area where technology directly impacts unit economics is the Medical Loss Ratio (MLR). Oscar leverages machine learning models for risk adjustment automation, ensuring that the company accurately assesses and prices the health risks of its members. This data-driven approach helps to mitigate adverse selection and stabilize MLR outcomes. Furthermore, its virtual care offerings and personalized health nudges, delivered through tools like Campaign Builder, encourage preventive care and guide members to cost-effective treatment pathways, thereby reducing avoidable claims and overall medical spend.
The +Oscar platform extends this technological advantage beyond its own insurance book, offering its modular tech services to other payors and providers. This strategy, likened to Amazon's AWS model, allows Oscar to monetize its significant investment in technology, potentially generating high-margin software revenue. While still a smaller part of the business, +Oscar provides an avenue for enhanced operating leverage, spreading fixed technology costs across a broader user base and improving the overall SG&A expense ratio.
Member engagement is another critical component of Oscar's tech strategy. The company's mobile-first experience, user-friendly apps, and integrated virtual services are designed to simplify healthcare navigation. By making healthcare more accessible and intuitive, Oscar aims to foster a more loyal customer base. Engaged members are more likely to renew their plans, reducing churn in the price-sensitive ACA market, and are more receptive to care coordination efforts that can lead to better health outcomes and lower long-term costs.
Oscar Health's operating model, while innovative, navigates a complex landscape filled with both significant challenges and compelling opportunities. The company's rapid growth in membership, reaching approximately 2.0 million by the end of 2025, up from 1.68 million in 2024, demonstrates strong market penetration, particularly within the Affordable Care Act (ACA) individual and small group segments. This expansion, coupled with a focus on Individual Coverage Health Reimbursement Arrangements (ICHRAs) which now account for about 15% of members and 20% of revenue, provides diversification and a potentially stickier member base.
However, the core challenge remains profitability, specifically managing the Medical Loss Ratio (MLR) amidst rising healthcare costs. The increase in Oscar's MLR to 87.4% in 2025 was primarily driven by higher average market morbidity and increased utilization, which were not fully offset by risk adjustment. This reflects an industry-wide battle with escalating medical and pharmacy expenses. Oscar's ability to execute on its projected 2026 MLR of 82.4–83.4% will be a crucial test of its cost containment strategies, including its tech-enabled care navigation and disciplined provider contracting.
On the opportunity side, Oscar's operating leverage is beginning to show. The SG&A expense ratio improved to 17.5% in 2025 from 19.1% in 2024, and is projected to further decline to 15.8–16.3% in 2026. This improvement is attributed to greater fixed cost leverage from its cloud-native tech platform, lower exchange fees, and disciplined cost management. As membership scales, the administrative costs per member should continue to decrease, amplifying the impact of its technology investments on the bottom line.
The +Oscar platform also represents a significant opportunity for future growth and margin expansion. By licensing its technology to other health systems and payors, Oscar can tap into a broader market without taking on additional insurance risk. This "insurance-enabled tech platform" model allows Oscar to leverage its battle-tested infrastructure, potentially generating high-margin software revenue and further improving its overall operating efficiency. Success here would validate its long-term vision of becoming a foundational technology layer for the healthcare ecosystem.
The highly regulated health insurance market, particularly the Affordable Care Act (ACA) exchanges where Oscar Health primarily operates, presents both structural support and significant policy-driven risks. Oscar's fortunes are inextricably linked to the stability and evolution of ACA policy, making regulatory changes a paramount consideration for investors. The company's growth to approximately 2.0 million members by the end of 2025 underscores its success in this market, but also highlights its exposure to its inherent volatility.
A major near-term variable is the fate of enhanced ACA subsidies. These subsidies, which make health insurance more affordable for millions of Americans, were scheduled to expire in 2025. While recent headlines have suggested potential extensions, the uncertainty surrounding their continuity poses a material risk. If subsidies lapse, higher net premiums could lead to reduced enrollment, particularly among healthier populations, potentially shifting Oscar's risk mix towards higher-acuity members and pressuring its MLR. Conversely, an extension would likely strengthen enrollment and stabilize the ACA risk pool, providing a significant tailwind.
Beyond subsidies, the broader regulatory environment dictates pricing adequacy, risk adjustment mechanisms, and compliance requirements. Oscar's ability to accurately price its plans and effectively execute on risk adjustment is crucial for profitability. The company has demonstrated pricing discipline, planning approximately 22% average premium increases for 2026, which are broadly aligned with ACA trends. However, these increases must be carefully balanced against competitive pressures and regulatory scrutiny to maintain enrollment and market share.
The competitive landscape is also shaped by regulation, as large integrated insurers like UnitedHealthcare and Cigna navigate the same rules but with deeper capital and scale. Oscar must continually defend its tech-led differentiation and pricing agility. Regulatory changes can also impact market entry and exit decisions, as seen with Oscar's strategic decision not to renew its Cigna+Oscar Small Group arrangement after December 31, 2024, to focus on more profitable segments. The company's disciplined expansion into markets with stable reimbursement structures is a hedge against potential regulatory volatility.
For investors considering Oscar Health (OSCR), the current landscape presents a high-risk, high-reward proposition. The company's shares are trading at $18.04, near the high end of analyst price targets, with a consensus "Hold" rating from Wall Street. This reflects a cautious optimism that the company can execute on its aggressive 2026 profitability targets, but also acknowledges the significant operational and policy-related risks.
Oscar's valuation, with a P/S ratio of 0.40, remains discounted compared to established healthcare peers, signaling market skepticism about its ability to achieve sustained profitability. However, if Oscar successfully delivers on its 2026 guidance – particularly achieving $250–$450 million in earnings from operations and significantly improving its MLR – this discount could narrow considerably, leading to a potential rerating of the stock. The company's strong revenue growth, projected at $18.7–$19.0 billion for 2026, indicates robust top-line momentum.
The investment thesis hinges on Oscar's ability to leverage its technology to drive down costs and enhance member engagement, thereby stabilizing its unit economics. The +Oscar platform offers an intriguing long-term optionality for high-margin software revenue, but its impact on overall profitability is still nascent. Investors should closely monitor the upcoming earnings report on May 6, 2026, for further insights into its progress toward these critical financial goals.
Given the inherent volatility of the ACA market and the execution challenges of a tech-driven insurer, OSCR is best suited for investors with a higher risk tolerance and a long-term horizon. The stock's beta of 1.93 underscores its sensitivity to broader market movements. While the path to consistent profitability remains challenging, Oscar's unique model and strategic focus on unit economics position it as a credible watchlist candidate for those who believe in the digitization of healthcare and the potential for a tech-enabled disruptor to thrive in a legacy industry.
Oscar Health is navigating a complex but potentially transformative period. Its ability to convert technological innovation into consistent financial performance, while deftly managing regulatory headwinds, will determine whether it truly turns the corner and delivers long-term value for shareholders.
Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.
